Announcement under Regulation 30 (LODR)- Earning Call Transcript
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Abate AS Industries reported FY2026 consolidated revenue of Rs.161.68 Crores, up 67% from Rs.96.6 Crores in FY2025. Profit after tax surged over 10x to Rs.12.3 Crores from Rs.1.1 Crores, and the company swung to positive operating cash flow of Rs.6.1 Crores versus negative cash flow in FY2025. The company operates across healthcare (eye care/ophthalmology), retail, education, and a Bahrain GCC presence, with healthcare now contributing 22% of revenue and targeted to reach 70-80% over time. CFO guided 18-20% EBITDA margins for the coming years (FY2026-FY2029), with the hospital segment currently delivering 70% gross margin. Management pegged future capex needs at around Rs.50 Crores, to be funded via disciplined capital allocation, with selective acquisitions under evaluation.
Sharp profitability jump, turnaround to positive operating cash flow, and clear multi-year margin guidance (18-20% EBITDA) signal improving business quality. Healthcare-led growth narrative and potential acquisition activity could support re-rating, though stock remains in early scaling phase with execution risk on the 70-80% healthcare mix target.